A small-molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase improves obesity, nephropathy and cardiomyopathy in obese ZSF1 rats.
Prolyl hydroxylase (PH) enzymes control the degradation of hypoxia-inducible factor (HIF), a transcription factor known to regulate erythropoiesis, angiogenesis, glucose metabolism, cell proliferation, and apoptosis. HIF-PH inhibitors (HIF-PHIs) correct anemia in patients with renal disease and in a...
Guardado en:
Autores principales: | Pierre E Signore, Guangjie Guo, Zhihua Wei, Weihua Zhang, Al Lin, Ughetta Del Balzo |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/29b1b5bc4f374084a6a0d5b79eeb70af |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Loss of Endothelial Hypoxia Inducible Factor‐Prolyl Hydroxylase 2 Induces Cardiac Hypertrophy and Fibrosis
por: Zhiyu Dai, et al.
Publicado: (2021) -
TRC150094 attenuates progression of nontraditional cardiovascular risk factors associated with obesity and type 2 diabetes in obese ZSF1 rats
por: Shitalkumar P Zambad, et al.
Publicado: (2011) -
Endothelin-1 inhibits prolyl hydroxylase domain 2 to activate hypoxia-inducible factor-1alpha in melanoma cells.
por: Francesca Spinella, et al.
Publicado: (2010) -
Hypoxia-inducible factor prolyl hydroxylase domain inhibitor may maintain hemoglobin synthesis at lower serum ferritin and transferrin saturation levels than darbepoetin alfa.
por: Chie Ogawa, et al.
Publicado: (2021) -
Structural basis for oxygen degradation domain selectivity of the HIF prolyl hydroxylases
por: Rasheduzzaman Chowdhury, et al.
Publicado: (2016)